The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2

被引:4
|
作者
Kraay, A. N. M. [1 ,2 ]
Gallagher, M. E. [3 ]
Ge, Y. [4 ]
Han, P. [5 ]
Baker, J. M. [5 ]
Koelle, K. [6 ]
Handel, A. [7 ,8 ]
Lopman, B. A. [5 ]
机构
[1] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61820 USA
[2] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA
[3] Johns Hopkins Univ Appl Phys Lab, Laurel, MD USA
[4] Univ Southern Mississippi, Sch Hlth Profess Publ Hlth, Hattiesburg, MS USA
[5] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA USA
[6] Emory Univ, Dept Biol, Atlanta, GA USA
[7] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA USA
[8] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA USA
关键词
booster; evolution; vaccination; COVID-19; non-pharmaceutical interventions; INFECTION;
D O I
10.1098/rsif.2022.0477
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Temporal Dynamics and Evolution of SARS-CoV-2 Demonstrate the Necessity of Ongoing Viral Genome Sequencing in Ontario, Canada
    Sjaarda, Calvin P.
    Guthrie, Jennifer L.
    Mubareka, Samira
    Simpson, Jared T.
    Hamelin, Bettina
    Wong, Henry
    Mortimer, Leanne
    Slinger, Robert
    McArthur, Andrew G.
    Desjardins, Marc
    McGeer, Allison
    Mazzulli, Tony
    Douchant, Katya
    Brabant-Kirwan, Danielle
    Fattouh, Ramzi
    Campigotto, Aaron
    Patel, Samir N.
    Fittipaldi, Nahuel
    Colautti, Robert I.
    Shethi, Prameet M.
    MSPHERE, 2021, 6 (03) : 1 - 9
  • [32] Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
    Norddahl, Gudmundur L.
    Melsted, Pall
    Gunnarsdottir, Kristbjorg
    Halldorsson, Gisli H.
    Olafsdottir, Thorunn A.
    Gylfason, Arnaldur
    Kristjansson, Mar
    Magnusson, Olafur T.
    Sulem, Patrick
    Gudbjartsson, Daniel F.
    Thorsteinsdottir, Unnur
    Jonsdottir, Ingileif
    Stefansson, Kari
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [33] Third booster dose SARS-CoV-2 vaccination in patients with autoimmune disease: correspondence
    Sookaromdee, P.
    Wiwanitkit, V
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (06) : 527 - 527
  • [34] Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
    Montagud, Ana C.
    Moragues, Raul
    Vicente-Alcalde, Nancy
    Montagud, Emilia
    Hurtado-Sanchez, Jose Antonio
    Tuells, Jose
    FRONTIERS IN PUBLIC HEALTH, 2025, 13
  • [35] Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
    Gudmundur L. Norddahl
    Pall Melsted
    Kristbjorg Gunnarsdottir
    Gisli H. Halldorsson
    Thorunn A. Olafsdottir
    Arnaldur Gylfason
    Mar Kristjansson
    Olafur T. Magnusson
    Patrick Sulem
    Daniel F. Gudbjartsson
    Unnur Thorsteinsdottir
    Ingileif Jonsdottir
    Kari Stefansson
    Nature Communications, 13
  • [36] Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
    Vasin, Andrey V.
    Stukova, Marina A.
    LANCET INFECTIOUS DISEASES, 2023, 23 (08): : 880 - 881
  • [37] SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials
    Peluso, Michael J.
    Williams, Meghann C.
    Campbell, Danielle M.
    Dee, Lynda
    Taylor, Jeff
    Ngo, Lynn H.
    Hoh, Rebecca
    Dube, Karine
    Sauceda, John A.
    Deeks, Steven G.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 89 (03) : E33 - +
  • [38] A seroprevalence study of SARS-CoV-2 and seasonal coronaviruses after the first SARS-CoV-2 circulation in New Caledonia, Pacific region
    Huet, Karl
    White, Michael
    Griffon, Anne-Fleur
    Bloch, Emma
    Magnat, Elodie
    Baudemont, Gaelle
    Inizan, Catherine
    Mena, Pascale Domingue
    Dupont-Rouzeyrol, Myrielle
    IJID REGIONS, 2024, 11
  • [39] SARS-CoV-2 vaccination in pregnancy
    Dalcin, Daniel
    Halperin, Scott A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (37) : E1274 - E1274
  • [40] Seasonal SARS-CoV-2 claim
    King, Anthony
    CHEMISTRY & INDUSTRY, 2022, 86 (01) : 6 - 6